Kozielski Frank, DeBonis Salvatore, Skoufias Dimitrios A
Institut de Biologie Structurale, CEA-CNRS-UJF, Grenoble, France.
Methods Mol Med. 2007;137:189-207. doi: 10.1007/978-1-59745-442-1_14.
The mitotic spindle is an important target for cancer chemotherapy. The main protein target for drugs in clinical use is tubulin, the building block of microtubules. In recent years, other proteins of the mitotic spindle have been identified as potential targets for the development of more specific drugs with the hope that these will have fewer side effects than known antimitotics (taxanes, vinca alkaloids). The human genome contains more than 40 members of the kinesin superfamily, with at least 12 of these involved in mitosis and cytokinesis. HsEg5 (also called KSP, kinesin spindle protein), a member of the kinesin-5 family, involved in the formation of the bipolar spindle, is a very promising target for cancer chemotherapy with specific inhibitors in Phase I and II clinical trails. Several successful approaches exist today to screen Eg5 for inhibitors, including phenotype-based assays and simple in vitro assays that explore the intrinsic enzymatic ATPase activity of Eg5. Here, we describe a robust and straightforward in vitro method to rapidly screen Eg5 for inhibitors. The assay can easily be adapted to other mitotic kinesins that may be identified in the future as potential drug targets, or simply to obtain specific kinesin inhibitors for use in "chemical genetics" to study the function of this important class of proteins.
有丝分裂纺锤体是癌症化疗的一个重要靶点。临床使用药物的主要蛋白质靶点是微管蛋白,它是微管的组成成分。近年来,有丝分裂纺锤体的其他蛋白质已被确定为开发更具特异性药物的潜在靶点,人们希望这些药物的副作用比已知的抗有丝分裂药物(紫杉烷类、长春花生物碱)更少。人类基因组包含40多个驱动蛋白超家族成员,其中至少12个参与有丝分裂和胞质分裂。HsEg5(也称为KSP,驱动蛋白纺锤体蛋白)是驱动蛋白-5家族的成员,参与双极纺锤体的形成,是癌症化疗中非常有前景的靶点,其特异性抑制剂正处于I期和II期临床试验阶段。目前存在几种成功的筛选Eg5抑制剂的方法,包括基于表型的检测方法以及探索Eg5内在酶促ATP酶活性的简单体外检测方法。在此,我们描述一种稳健且直接的体外方法,用于快速筛选Eg5的抑制剂。该检测方法可轻松适用于未来可能被确定为潜在药物靶点的其他有丝分裂驱动蛋白,或者仅仅用于获得用于“化学遗传学”以研究这类重要蛋白质功能的特异性驱动蛋白抑制剂。